Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.65M$3.65Mderived−16.4% vs Q4 2023 Net Income-$1.73M-$1.73MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,748,000−16.4% Operating Incomederived-$1,617,000N/M Operating Cash Flowderived-$1,916,000N/M Margins · derivedGross margin47.8%+0.0 pt vs Q4 2023
Operating margin-44.3%−21.2 pt vs Q4 2023
Net margin-47.4%−24.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end